Mosbrooker Eric 4
4 · Avidity Biosciences, Inc. · Filed Oct 7, 2025
Insider Transaction Report
Form 4
Mosbrooker Eric
Chief Commercial Officer
Transactions
- Sale
Common Stock
2025-10-03$45.38/sh−6,562$297,771→ 55,000 total - Exercise/Conversion
Common Stock
2025-10-03$9.05/sh+6,562$59,386→ 61,562 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-03−6,562→ 177,188 totalExercise: $9.05Exp: 2033-12-31→ Common Stock (6,562 underlying)
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 11, 2024.
- [F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $47.21. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/48th of the total number of shares subject to the option shall vest on each monthly anniversary of January 1, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.